IBJNews

Lilly’s experimental diabetes drug helps patients lose weight

Back to TopCommentsE-mailPrintBookmark and Share

Patients taking Eli Lilly and Co.’s experimental diabetes drug dulaglutide lost weight and had side effects that were manageable, the company said over the weekend after releasing more data from three final-stage clinical trials.

Lilly released top-line results from the company-sponsored trials last year, when it reported more patients taking the therapy had blood glucose levels indicating their disease was under control than those given Merck & Co.’s top-selling drug Januvia and Bristol-Myers Squibb Co.’s Byetta. The data released Saturday had details of those results, as well as side effect and weight-loss information.

Lilly’s drug, if approved, may be a significant competitor to Novo Nordisk A/S’s Victoza, which generated $1.64 billion in 2012, according to data compiled by Bloomberg. A clinical trial comparing the drugs may report results by the end of the year.

“We look at the space and we feel we have an opportunity to offer a significant new product,” said Sherry Martin, senior medical director for diabetes development at Indianapolis-based Lilly. The company plans to submit the drug to U.S. regulators for approval by the end of this year, she said. The studies were presented as part of the American Diabetes Association meeting in Chicago.

“Dulaglutide data suggests a profile that may be sufficient to demonstrate superiority versus Victoza in the head-to-head study,” said Sachin Jain, an analyst with Bank of America Corp. In a June 17 note to clients, he cut his rating on Novo shares to neutral from buy because of the Lilly data. The drug “represents a significant threat to Victoza market share,” Jain said.

Diabetes drugs

Merck, Bristol-Myers, and Johnson & Johnson also have competing diabetes therapies on the market. Dulaglutide is in a class known as GLP-1 receptor agonists. The injection mimics the function of a digestive hormone that stimulates the pancreas to produce insulin after meals.

The class of drugs, along with another group called DPP-4 that includes Januvia, are under scrutiny by U.S. regulators over whether they may cause cancer. The Food and Drug Administration has asked companies to gather more data on the safety of the therapies.

Diabetes occurs when a person’s blood sugar gets too high and the body doesn’t produce enough insulin or doesn’t use insulin effectively to control the level. An estimated 347 million people worldwide, including about 25.8 million Americans, have the disease according to global health authorities. The condition can lead to heart disease, stroke and blindness.

Sales estimates

Dulaglutide is projected to sell $835 million in 2018, according to the average of six analysts’ estimates compiled by Bloomberg. Martin said the drug would be the only weekly injection in the class that doesn’t require patients to prepare the dose for administration.

In about 900 patients taking dulaglutide, 54 percent of those on the higher dose had hemoglobin A1c scores under 7 percent, a measure of whether the disease is in check. That compared with 31 percent on Merck’s Januvia.

In another trial of about 1,000 patients taking dulaglutide or Bristol-Myers’s Byetta, along with two other diabetes drugs, 71 percent of patients on dulaglutide had hemoglobin A1c under 7 percent after a year, compared with 59 percent on Byetta.

Mark Schoenebaum, an analyst with ISI Group LLC in New York, was less positive about the results. Dulaglutide looks “undifferentiated from J&J’s Invokana and Bristol-Myer’s Bydureon,” Schoenebaum said in a June 17 note to clients, after the trial results became available online but before they were released for publication by news outlets. “This is in-line or slightly better than investors’ expectations.”

Weight loss

Patients also lost more weight on dulaglutide than on the other two medications. Those on the highest dose of Lilly’s drug lost 2.9 kilograms after two years, compared with 1.8 kilograms for patients on Merck’s Januvia. In the other trial, they lost 1 kilogram after one year on the dulaglutide compared with 0.7 kilograms with Bristol-Myers’s drug.

“The modest weight loss is important,” Martin said. “Other medications that can deliver this glycemic control do that with weight gain.”

Lilly also reported side effect data from the trials. Drugs such dulaglutide can cause gastrointestinal upset while patients get adjusted to the medication, though it usually goes away after a few days, Martin said. Less than 3 percent of patients quit taking Lilly’s drug because of the side effect, she said.

Lilly shares were down 1.6 percent Monday morning, to $48.92 each, along with a general fall in the market.

ADVERTISEMENT

  • Bravo Lilly diabetes treatment
    (The drug dulaglutide, a once-weekly injectable that is meant for adult-onset diabetes, helped patients lose weight and control their blood sugar better than several already-marketed drugs, Lilly’s studies showed._ WOW! A new diabetes treatment that has beneficial weight loss as a side effect.This is similar to Metformin propertie. Remember-Zyprexa (Olanzapine) Diabetes connection conflict of interest. Eli Lilly made $70 billion to date,paid $1.4 billion in criminal fines. Thousands got diabetes as Zyprexa side effect and have to take Lilly insulin to treat the diabetes that was caused by their Zyprexa. Eli Lilly Zyprexa can ruin your Pancreas and make you a type 2 diabetic in just a few months of use.I took it 1996-2000 and now am a diabetic for it. 'Atypical' antipsychotic Zyprexa is the worst offender of them all.Google-Haszard Zyprexa - got a page up. -Daniel Haszard

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Again, Maria.... how much are YOU contributing? The man doesn't HAVE to give a red cent! What don't you get about that? And, I know this might actually require some actual "facts", but can you please point me to the parking garage that the city gave to him?

  2. Another internet tuff guy I see. And what would the basis of taking the person to jail? If they were drunk, yea. But if not, there would be no jailable offense. All these gestapo, Nazi, jackboots are running SCARED. When the SHTF in this country who's side are you going to be on? The citzens, or the establishment? Better make up your mind quick because it's not far off. I would rather be trying to make friends than enemies. But no worries my "friend", God will take care of you and your likes in good time. It tells us that in the bible. If you stand, support and help carry out the plans of evil rulers, you will NOT be spared the wrath of God. That simple. All you can do is repent now and ask God to forgive you.

  3. Yes, Ersal, thank you for donating a whole $75,000, while the city gives you a parking garage for free and is going to pay for a multi million dollar stadium for you. I'd be donating money too if I was on welfare.

  4. I live and work in Broad Ripple and agree 100% that the traffic is not a significant problem. It can be slow at some times, but hey...this is an urban area. As for the development itself...HOORAY. Office and retail development brings people during the day, something that our community needs much more of. Thank goodness people are finally waking up to take advantage of the serene White River views. The BRVA land us committee endorsed the project because they know how these kind of projects help offset the cries of "too many bars". Pray that this development, and the proposed major investment by Browning, move forward. And remember Good Earth, these will mean hundreds of daytime people - potential shoppers for your store.

  5. Under current, previous existing law, this new law would be unconstitutional. Not that supposedly having to have a driver's license to drive isn't in the first place.

ADVERTISEMENT